ArticleCell death & disease2026
MND1 reduces breast cancer chemosensitivity by promoting RAD51-mediated homologous recombination repair.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Breast cancer remains a major global health challenge for women. Chemotherapy resistance is a key driver of breast cancer recurrence and metastasis. Although meiotic nuclear division 1 (MND1) has been characterized as an oncogenic factor involved in mitotic progression and homologous recombination (HR), the precise molecular mechanisms underlying these MND1-mediated processes remain unclear. The expression of MND1 in breast cancer cell lines was evaluated by RT-qPCR and western blot. The functional effects of MND1 were assessed through a series of in vitro and in vivo assays, including cell proliferation assays, determination of resistance curves, DNA damage detection and flow cytometry. Protein interactions among MND1, RAD51, and USP5 were determined by co-immunoprecipitation assays. Transcriptional regulation of MND1 by E2F1 and promoter methylation status were analyzed using luciferase reporter assays and bisulfite sequencing PCR, respectively. We demonstrated that MND1 is upregulated in breast cancer and associated with cancer progression and cisplatin resistance. Mechanistically, MND1 promotes HR repair by recruiting USP5 to deubiquitinate and stabilize RAD51. Furthermore, E2F1 induces promoter hypomethylation and transcriptionally activates MND1 by binding to its promoter. Our findings establish a role for MND1 in regulating chemosensitivity and provide new insights into relevant gene interaction networks. The identified E2F1/MND1/USP5/RAD51 feedback loop underscores the potential of MND1 as a therapeutic target for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.